咪唑斯汀对常年性变应性鼻炎患者生活质量的影响

目的观察咪唑斯汀对常年性变应性鼻炎患者生活质量的影响。方法进行随机、双盲、有效剂和安慰剂的平行对照研究，应用生活质量医学成果研究简表36项健康调查（Medical Outcome Study Short-Form 36-items Health Survey，MOSSF-36）问卷中文版进行调查。常年变应性鼻炎患者60例，年龄14～62岁。随机将患者分为3组：咪唑斯汀组26例：男12例，女14例；西替利嗪组22例：男12例，女10例；安慰剂组12例：男7例，女5例。3种药物服用方法均为每天1次，每次1片，共服用3周，于服药前及服药后每天记录症状记分，于服药前、服药后第1和第3周采用SF-36生活质量问卷分别进行生活质量评价，评价内容包含36个项目，主要包括患者自己对功能状态、幸福和健康的评价。结果治疗前3组间患者症状记分、生活质量记分差异无统计学意义。服药1周和3周后咪唑斯汀组症状明显改善，生活质量明显提高（P值均〈0．001），与西替利嗪组相当，安慰剂组未见明显改善。结论咪唑斯汀能有效改善常年性变应性鼻炎患者的过敏症状，同时能提高患者的生活质量，安慰剂虽然也能短时间内改善部分患者症状，但不能提高患者的生活质量记分。

Mizolastine improves the quality of life in patients with perennial allergic rhinitis: A randomized, double blind, controlled study

Objective To assess the effect of Mizolastine on quality of life (QOL) in patients with perennial allergic rhinitis. Methods A randomized, double-blind, placebo-controlled study was carried out with Mizolastine in sixty patients with perennial allergic rhinitis. QOL was measured by using the Medical Outcome Study Short-Form Health Survey ( SF-36) questionnaire ( Chinese version). Mizolastine (10 mg once daily, 26 patients) , Cetirizine (10 mg once daily, 22 patients) or placebo (12 patients) was given for 3 weeks. The SF-36 questionnaire was administered at the start of treatment and after 1 and 3 weeks of treatment. Symptom-medication scores were measured daily during the study. Results After the run-in period ( baseline) , there were no significant differences among the Mezolastine, Cetirizine and placebo groups in terms of symptoms or QOL scores. After 1 and 3 weeks of treatment, symptoms scores were significantly decreased and QOL scores significantly improved in the Mezolastine group and Cetirizine group in comparison with the placebo group ( both P <0.001 , x2 test). All of the eight QOL dimensions were significantly improved (from P =0. 001 to P < 0. 0001 , F test) after 1 and 3 weeks of Mizolastine treatment compared with placebo. There was no improvement in the placebo group. Conclusions Mizolastine can not only decrease symptoms scores but also improve the QOL in patients with perennial allergic rhinitis. Placebo can relieve the symptoms but can not improve the QOL.